Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028987 · ClinicalTrials.gov registry record · Phase 4
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03028987: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT03028987 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028987, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associated with the T-cell immune response.
Interventions
- BIOLOGICAL Fluzone®
- BIOLOGICAL FluMist®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-11-19 |
| Est. Completion | 2015-11-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028987
The ClinicalTrials.gov registry entry for NCT03028987 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone® is the first listed.
NCT03028987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028987 about?
NCT03028987 is a clinical study titled "Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)". The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associat...
What is the current status of trial NCT03028987?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2014-11-19. Estimated completion is 2015-11-18.
What interventions are being tested in trial NCT03028987?
The interventions under investigation include: Fluzone® (BIOLOGICAL), FluMist® (BIOLOGICAL).
Who is sponsoring clinical trial NCT03028987?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.